Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...
Novo Nordisk’s icodec-abae is now approved in the US for type 2 diabetes only, after a prior rejection partly due to concerns about hypoglycemia in type 1 diabetes.
The FDA’s decision is based on data from the ONWARDS Phase IIIa clinical programme involving nearly 2,680 adults.
Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient-reported outcomes compared to Taltz monotherapy in TOGETHER-PsA ...
Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient-reported outcomes compared to Taltz monotherapy in TOGETHER-PsA study ...
The FDA has approved the first weekly insulin shot for adults with type 2 diabetes, offering a new alternative to daily injections.
Everyday Health on MSN
Once-a-week insulin shot could be a game changer for type 2 diabetes
Some patients with type 2 diabetes will be able to switch from daily insulin injections to this first-of-its-kind once-weekly ...
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin ...
(1,2) "Awiqli (R) is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes. It's helping to reframe what basal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results